Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer

Gregory Tiesi, Wungki Park, Meredith Gunder, Gustavo Rubio, Michael Berger, Bach Ardalan, Alan Livingstone, Dido Franceschi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background Neoadjuvant treatment is standard for locally advanced esophageal cancer. However, whether the addition of radiation to neoadjuvant regimen improves survival remains unclear. The aim of this study was to compare survival in locally advanced esophageal cancer treated with neoadjuvant chemotherapy versus chemoradiation. Materials and methods A prospectively maintained database of esophagectomies (1999-2012) was analyzed. We identified 297 patients with locally advanced esophageal cancer that underwent either neoadjuvant chemotherapy (n = 231) or chemoradiation (n = 66) followed by esophagectomy. Pretreatment and pathologic staging were compared to assess response. Overall survival was recorded. Results Most patients in the chemotherapy and chemoradiation groups had pretreatment stage III disease (66.7% versus 65.2%; P = 0.44). Median follow-up was 79.3 and 64.9 mo for chemotherapy and chemoradiation cohorts, respectively. Complete response rate was higher in chemoradiation than chemotherapy groups (30.3% versus 13.8%; P < 0.001). Overall survival was similar between complete responders in both groups (median not reached versus 121.1 mo; chemotherapy versus chemoradiation). However, partial responders in the chemotherapy cohort had improved median survival (147.2 mo) versus those in the chemoradiation cohort (83.7 mo, P < 0.03). Within the chemotherapy-only group, partial responders had improved survival compared with nonresponders (P = 0.041); however, there was no difference in survival between partial and complete responders (P = 0.36). Conclusions In patients undergoing esophagectomy for locally advanced esophageal cancer, neoadjuvant chemotherapy was associated with an equivalent overall survival, when compared with neoadjuvant chemoradiotherapy. Adding neoadjuvant radiation may enhance complete response rates but does not appear to be associated with improved survival.

Original languageEnglish (US)
Pages (from-to)65-72
Number of pages8
JournalJournal of Surgical Research
Volume216
DOIs
StatePublished - Aug 1 2017

Fingerprint

Neoadjuvant Therapy
Esophageal Neoplasms
Drug Therapy
Survival
Esophagectomy
Radiation
Chemoradiotherapy
Databases

Keywords

  • Esophageal neoplasm
  • Neoadjuvant treatment

ASJC Scopus subject areas

  • Surgery

Cite this

Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer. / Tiesi, Gregory; Park, Wungki; Gunder, Meredith; Rubio, Gustavo; Berger, Michael; Ardalan, Bach; Livingstone, Alan; Franceschi, Dido.

In: Journal of Surgical Research, Vol. 216, 01.08.2017, p. 65-72.

Research output: Contribution to journalArticle

Tiesi, Gregory ; Park, Wungki ; Gunder, Meredith ; Rubio, Gustavo ; Berger, Michael ; Ardalan, Bach ; Livingstone, Alan ; Franceschi, Dido. / Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer. In: Journal of Surgical Research. 2017 ; Vol. 216. pp. 65-72.
@article{5d925f9190924ffda1f8f8bb6f34cd4a,
title = "Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer",
abstract = "Background Neoadjuvant treatment is standard for locally advanced esophageal cancer. However, whether the addition of radiation to neoadjuvant regimen improves survival remains unclear. The aim of this study was to compare survival in locally advanced esophageal cancer treated with neoadjuvant chemotherapy versus chemoradiation. Materials and methods A prospectively maintained database of esophagectomies (1999-2012) was analyzed. We identified 297 patients with locally advanced esophageal cancer that underwent either neoadjuvant chemotherapy (n = 231) or chemoradiation (n = 66) followed by esophagectomy. Pretreatment and pathologic staging were compared to assess response. Overall survival was recorded. Results Most patients in the chemotherapy and chemoradiation groups had pretreatment stage III disease (66.7{\%} versus 65.2{\%}; P = 0.44). Median follow-up was 79.3 and 64.9 mo for chemotherapy and chemoradiation cohorts, respectively. Complete response rate was higher in chemoradiation than chemotherapy groups (30.3{\%} versus 13.8{\%}; P < 0.001). Overall survival was similar between complete responders in both groups (median not reached versus 121.1 mo; chemotherapy versus chemoradiation). However, partial responders in the chemotherapy cohort had improved median survival (147.2 mo) versus those in the chemoradiation cohort (83.7 mo, P < 0.03). Within the chemotherapy-only group, partial responders had improved survival compared with nonresponders (P = 0.041); however, there was no difference in survival between partial and complete responders (P = 0.36). Conclusions In patients undergoing esophagectomy for locally advanced esophageal cancer, neoadjuvant chemotherapy was associated with an equivalent overall survival, when compared with neoadjuvant chemoradiotherapy. Adding neoadjuvant radiation may enhance complete response rates but does not appear to be associated with improved survival.",
keywords = "Esophageal neoplasm, Neoadjuvant treatment",
author = "Gregory Tiesi and Wungki Park and Meredith Gunder and Gustavo Rubio and Michael Berger and Bach Ardalan and Alan Livingstone and Dido Franceschi",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.jss.2017.03.022",
language = "English (US)",
volume = "216",
pages = "65--72",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer

AU - Tiesi, Gregory

AU - Park, Wungki

AU - Gunder, Meredith

AU - Rubio, Gustavo

AU - Berger, Michael

AU - Ardalan, Bach

AU - Livingstone, Alan

AU - Franceschi, Dido

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Background Neoadjuvant treatment is standard for locally advanced esophageal cancer. However, whether the addition of radiation to neoadjuvant regimen improves survival remains unclear. The aim of this study was to compare survival in locally advanced esophageal cancer treated with neoadjuvant chemotherapy versus chemoradiation. Materials and methods A prospectively maintained database of esophagectomies (1999-2012) was analyzed. We identified 297 patients with locally advanced esophageal cancer that underwent either neoadjuvant chemotherapy (n = 231) or chemoradiation (n = 66) followed by esophagectomy. Pretreatment and pathologic staging were compared to assess response. Overall survival was recorded. Results Most patients in the chemotherapy and chemoradiation groups had pretreatment stage III disease (66.7% versus 65.2%; P = 0.44). Median follow-up was 79.3 and 64.9 mo for chemotherapy and chemoradiation cohorts, respectively. Complete response rate was higher in chemoradiation than chemotherapy groups (30.3% versus 13.8%; P < 0.001). Overall survival was similar between complete responders in both groups (median not reached versus 121.1 mo; chemotherapy versus chemoradiation). However, partial responders in the chemotherapy cohort had improved median survival (147.2 mo) versus those in the chemoradiation cohort (83.7 mo, P < 0.03). Within the chemotherapy-only group, partial responders had improved survival compared with nonresponders (P = 0.041); however, there was no difference in survival between partial and complete responders (P = 0.36). Conclusions In patients undergoing esophagectomy for locally advanced esophageal cancer, neoadjuvant chemotherapy was associated with an equivalent overall survival, when compared with neoadjuvant chemoradiotherapy. Adding neoadjuvant radiation may enhance complete response rates but does not appear to be associated with improved survival.

AB - Background Neoadjuvant treatment is standard for locally advanced esophageal cancer. However, whether the addition of radiation to neoadjuvant regimen improves survival remains unclear. The aim of this study was to compare survival in locally advanced esophageal cancer treated with neoadjuvant chemotherapy versus chemoradiation. Materials and methods A prospectively maintained database of esophagectomies (1999-2012) was analyzed. We identified 297 patients with locally advanced esophageal cancer that underwent either neoadjuvant chemotherapy (n = 231) or chemoradiation (n = 66) followed by esophagectomy. Pretreatment and pathologic staging were compared to assess response. Overall survival was recorded. Results Most patients in the chemotherapy and chemoradiation groups had pretreatment stage III disease (66.7% versus 65.2%; P = 0.44). Median follow-up was 79.3 and 64.9 mo for chemotherapy and chemoradiation cohorts, respectively. Complete response rate was higher in chemoradiation than chemotherapy groups (30.3% versus 13.8%; P < 0.001). Overall survival was similar between complete responders in both groups (median not reached versus 121.1 mo; chemotherapy versus chemoradiation). However, partial responders in the chemotherapy cohort had improved median survival (147.2 mo) versus those in the chemoradiation cohort (83.7 mo, P < 0.03). Within the chemotherapy-only group, partial responders had improved survival compared with nonresponders (P = 0.041); however, there was no difference in survival between partial and complete responders (P = 0.36). Conclusions In patients undergoing esophagectomy for locally advanced esophageal cancer, neoadjuvant chemotherapy was associated with an equivalent overall survival, when compared with neoadjuvant chemoradiotherapy. Adding neoadjuvant radiation may enhance complete response rates but does not appear to be associated with improved survival.

KW - Esophageal neoplasm

KW - Neoadjuvant treatment

UR - http://www.scopus.com/inward/record.url?scp=85019600477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019600477&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2017.03.022

DO - 10.1016/j.jss.2017.03.022

M3 - Article

VL - 216

SP - 65

EP - 72

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

ER -